A new Parkinson’s drug is a long-acting version of a cheap generic. Should it cost $30,000 a year?

Adamas Pharmaceuticals (ADMS) had five minutes on Thursday night to feel good about its first U.S. drug approval before sniping over pricing kicked in.

The FDA approved the new Adamas product, to be marketed under the brand name Gocovri, to reduce dyskinesia (involuntary movements) experienced by some Parkinson’s disease patients on levodopa therapy. Adamas noted Thursday that Gocovri is the first and only FDA-approved medicine for this indication, but the claim comes with an asterisk.

 

Source; https://www.statnews.com/2017/08/25/adamas-parkinsons-pricing/